On Tuesday, Shares of Groupon, Inc. (NASDAQ:GRPN), showed no change to $4.29.
Groupon and the Lincoln Park Chamber of Commerce (LPCC) declared the launch of a hyperlocal, dedicated Groupon collection: We Love Lincoln Park, showcasing an entire neighborhood and some of its greatest local businesses. Started yesterday and running through September 10, local Lincoln Park merchants — whose offerings range from ethnic cuisines to fun things to do — are running exclusive offers with Groupon to assist drive greater awareness of all the products, services and experiences in Lincoln Park.
The collection also features a philanthropic element — shoppers can donate to one or several participating local organizations (in multiples of $10) through a Groupon Grassroots philanthropic campaign. 100% of donations go directly to the chosen charity (or charities).
Groupon, Inc. operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount worldwide. It also offers deals on products for which it acts as the merchant of record.
Shares of International Game Technology PLC (NYSE:IGT), inclined 2.79% to $19.51, during its last trading session.
International Game Technology stated financial results for the second quarter and six months ended June 30, 2015. This is IGT’s inaugural earnings declaration since the combination of GTECH S.p.A. and International Game Technology was accomplished on April 7, 2015.
In a separate news release issued recently, the Company’s Board of Directors initiated a quarterly cash dividend of $0.20 per ordinary share. The first cash dividend is payable on September 10, 2015 to shareholders of record as of the close of business on August 26, 2015.
International Game Technology PLC operates and provides a range of services and technology products across lotteries, machine gaming, sports betting, and interactive gaming markets in North America, Asia, and Europe.
Finally, Puma Biotechnology, Inc. (NYSE:PBYI), ended its last trade with 5.85% gain, and closed at $97.01.
Puma Biotechnology, declared financial results for the second quarter ended June 30, 2015.
Unless otherwise stated, all comparisons are for the second quarter and first half of the year 2015 contrast to the second quarter and first half of the year 2014.
Based on accounting principles generally accepted in the United States (GAAP), Puma stated a net loss applicable to common stock of $64.7 million, or $2.01 per share, for the second quarter of 2015, contrast to a net loss of $38.8 million, or $1.29 per share, for the second quarter of 2014. Net loss applicable to common stock for the first half of 2015 was $117.1 million, or $3.68 per share, contrast to $58.6 million, or $1.96 per share, for the first half of 2014.
Adjusted net loss applicable to common stock was $36.5 million, or $1.13 per share, for the second quarter of 2015, contrast to adjusted net loss applicable to common stock of $31.6 million, or $1.05 per share, for the second quarter of 2014. Adjusted net loss applicable to common stock for the first half of 2015 was $68.8 million, or $2.16 per share, contrast to $46.3 million, or $1.55 per share, for the first half of 2014. Adjusted net loss applicable to common stock excludes stock-based compensation expense, which represents a noteworthy portion of overall expense and has no impact on the cash position of the Company.
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
